EXAGEN INC.
Vista, CA · CIK 0001274737 · Medtech · Public
Laboratory tests and diagnostic assays for autoimmune disease detection and characterization
exagen.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $85M
- 24 Form D · Feb 2019
- 92 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 18
- 6 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $1,999,995 | |
| Private capital raised | Form D · SEC | $4,910,490 | |
| Private capital raised | Form D · SEC | $4,910,423 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $11,986,707 | |
| Private capital raised | Form D · SEC | $5,306,834 | |
| Private capital raised | Form D · SEC | $123,745 | |
| Private capital raised | Form D · SEC | $5,016,977 | |
| Private capital raised | Form D · SEC | $3,950,000 | |
| Private capital raised | Form D · SEC | $1,818,767 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $2,999,766 | |
| Private capital raised | Form D · SEC | $16,817,541 | |
| Private capital raised | Form D · SEC | $2,100,000 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $995,889 | |
| Private capital raised | Form D · SEC | $995,889 | |
| Private capital raised | Form D · SEC | $995,889 | |
| Private capital raised | Form D · SEC | $995,889 | |
| Private capital raised | Form D · SEC | $1,453,000 | |
| Private capital raised | Form D · SEC | $1,314,500 | |
| Private capital raised | Form D · SEC | $3,749,993 | |
| Private capital raised | Form D · SEC | $6,586,411 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1945 | ILLIONIX, LLC | — | — |
| 1946 | CVRx, Inc. | — | $126M |
| 1947 | Ivenix, Inc. | — | $84M |
| 1948 | EXAGEN INC. | — | $85M |
| 1949 | Venus Concept Inc. | — | $196M |
| 1950 | KENTUCKY IMAGING TECHNOLOGIES, LLC | — | — |
| 1951 | Intact Vascular | — | $80M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kamal AdawiExecutive Officer
- John Alsobrook, IIExecutive Officer
- John BessoneDirector
- David BilvinDirector
- Brian BirkDirector
- David BlivinDirector
- Daniel BurrellDirector
- Lisa DavisExecutive Officer
- Thierry DervieuxExecutive Officer
- Scott GlennDirector · Executive Officer
- Mark HazeltineExecutive Officer
- Curt LaBelleDirector
- Curtis LaBelleDirector
- Beto PallaresDirector
- Ebetuel PallaresDirector
- Dinesh PatelDirector
- John RadakDirector
- Sam RiccitelliDirector
- Fortunato RoccaDirector · Executive Officer
- Ron RoccaExecutive Officer
- Stephanie SpongDirector
- Todd StevensDirector
- Wendy SwedickExecutive Officer
- James TullisDirector
- Waneta TuttleDirector
- Michael WalshDirector
- Arthur WeinsteinDirector
- Frank WitneyDirector
Patents
- Methods For Diagnosing Systemic Lupus Erythematosusapplication
- Methods For Treating And Diagnosing Systemic Lupus Erythematosusapplication
- Methods For Treating And Diagnosing Systemic Lupus Erythematosusgranted
- Methods For Diagnosing Systemic Lupus Erythematosusgranted
- Methods For Diagnosing Systemic Lupus Erythematosusgranted
- Methods For Diagnosing Systemic Lupus Erythematosusgranted
- Methods For Treating And Diagnosing Systemic Lupus Erythematosus By Measuring Levels Of Biomarkers, Such As Erythrocyte-bound C4D, B-lymphocyte-bound C4D, Anti-sjogren's Syndrome Type B Antigen, SCL-70 Antibody, JO-1 Antibody, And Anti-centromere Protein B, In Subjects; Identifying Subjects As Having Systemic Lupus Erythematosus Based On Biomarker Levels; And Treating Subjects For Systemic Lupus Erythematosusapplication
- Methods for treating and diagnosing Systemic Lupus Erythematosusgranted
- Methods For Diagnosing, Prognosing And Monitoring Treatment For Thrombosis In Subjects With Systemic Lupus Erythematosusapplication
- Methods For Diagnosing Systemic Lupus Erythematosusapplication
- Methods for Diagnosing Systemic Lupus Erythematosusgranted
- Methods For Diagnosing, Prognosing And Monitoring Treatment For Thrombosis In Subjects With Systemic Lupus Erythematosusapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.